The German Cancer Research Center (DKFZ) has entered into an alliance with Telix Pharmaceuticals (TLX) in the field of image-guided surgery for prostate cancer.
DKFZ and Heidelberg University Clinic, Germany, have developed a next-generation radiotracer based on 68Ga-PSMA-11 (currently under development by Telix as TLX591-CDx and marketed as illumetTM in the United States) that incorporates a fluorophore (a fluorescing agent) in addition to the ability to molecularly target radiation for imaging with Positron Emission Tomography (PET).
This has resulted in a capability to simultaneously image prostate cancer with PET as well as provide intra-operative surgical guidance through fluorescence (optimal) imaging, reported Telix Pharmaceuticals press release. Image-guided (fluorescence) imaging is a standard embedded feature of modern robotic surgery platforms.
Telix Group CEO Dr. Christian Behrenbruch
Dr. Behrenbruch noted, “The astonishing research of our colleagues at DKFZ and Heidelberg has tremendous potential in improving the quality and efficiency of using image-guided techniques for robotic surgery. To date, Telix has focused on using PSMA imaging in the post-prostatectomy biochemical recurrence setting. This collaboration will explore how the combination of PET and image-guided surgery can be used to improve outcomes during prostatectomy, further expanding the impact of molecular imaging in the management of prostate cancer.”
Terms of Collaboration
Telix, DKFZ and affiliated researchers will conduct the necessary translational research studies to study and evaluate the technology in the surgical setting. The agreement includes a fully negotiated, exclusive option to license the technology for commercial development.
German Cancer Research Center (DKFZ)
DKFZ is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In over 90 divisions and research groups, they have more than 3,000 employees, of which more than 1,200 are scientists investigating the mechanisms of cancer while also identifying cancer risk factors and prevention research. They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is based in Melbourne, Australia with international operations in Brussels (EU), Kyoto (Japan) and Indianapolis (USA). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet need in renal, prostate and brain (glioblastoma) cancer. It is listed on the Australian Securities Exchange as TLX.